[go: up one dir, main page]

PL1865940T3 - Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych - Google Patents

Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych

Info

Publication number
PL1865940T3
PL1865940T3 PL06748476T PL06748476T PL1865940T3 PL 1865940 T3 PL1865940 T3 PL 1865940T3 PL 06748476 T PL06748476 T PL 06748476T PL 06748476 T PL06748476 T PL 06748476T PL 1865940 T3 PL1865940 T3 PL 1865940T3
Authority
PL
Poland
Prior art keywords
protease inhibitors
cysteine protease
ketoamide compounds
alpha ketoamide
alpha
Prior art date
Application number
PL06748476T
Other languages
English (en)
Inventor
Michael Graupe
John O Link
Michael G Roepel
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of PL1865940T3 publication Critical patent/PL1865940T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
PL06748476T 2005-03-21 2006-03-17 Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych PL1865940T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66397005P 2005-03-21 2005-03-21
US68462305P 2005-05-24 2005-05-24
PCT/US2006/010063 WO2006102243A2 (en) 2005-03-21 2006-03-17 Alpha ketoamide compounds as cysteine protease inhibitors
EP06748476A EP1865940B1 (en) 2005-03-21 2006-03-17 Alpha ketoamide compounds as cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
PL1865940T3 true PL1865940T3 (pl) 2013-06-28

Family

ID=37024483

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06748476T PL1865940T3 (pl) 2005-03-21 2006-03-17 Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych

Country Status (22)

Country Link
US (4) US7488848B2 (pl)
EP (2) EP1865940B1 (pl)
JP (2) JP5209466B2 (pl)
KR (1) KR101447897B1 (pl)
AU (1) AU2006227254B2 (pl)
BR (1) BRPI0609695A2 (pl)
CA (1) CA2602175C (pl)
CY (1) CY1114075T1 (pl)
DK (1) DK1865940T3 (pl)
EA (2) EA017874B1 (pl)
ES (1) ES2400582T3 (pl)
HR (1) HRP20130419T1 (pl)
IL (2) IL186102A (pl)
LV (1) LV13669B (pl)
MX (1) MX2007011617A (pl)
NO (2) NO340619B1 (pl)
NZ (1) NZ561681A (pl)
PL (1) PL1865940T3 (pl)
PT (1) PT1865940E (pl)
RS (1) RS52762B (pl)
TW (1) TWI384982B (pl)
WO (1) WO2006102243A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1865940B1 (en) * 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
US8431733B2 (en) 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
EP2361243B9 (en) * 2008-11-13 2014-06-11 Virobay, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
CN102264710B (zh) * 2008-12-19 2014-11-05 美迪维尔英国有限公司 半胱氨酸蛋白酶抑制剂
IN2012DN04915A (pl) * 2009-12-10 2015-09-25 Medivir Uk Ltd
EP2582660B1 (en) * 2010-06-16 2015-07-22 Medivir UK Ltd New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
WO2012151319A1 (en) 2011-05-02 2012-11-08 Virobay, Inc. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
US20120329837A1 (en) * 2011-06-17 2012-12-27 Virobay, Inc. Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
US11370761B2 (en) 2017-01-23 2022-06-28 Nippon Chemiphar Co., Ltd. Voltage-dependent T-type calcium channel inhibitor
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CN116589425A (zh) * 2022-12-29 2023-08-15 百放英库医药科技(北京)有限公司 组织蛋白酶l抑制剂

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
US5187173A (en) * 1991-12-27 1993-02-16 Sterling Winthrop Inc. 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU4544993A (en) * 1992-06-24 1994-01-24 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
JP3599287B2 (ja) 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
JPH08208462A (ja) * 1994-11-24 1996-08-13 Takeda Chem Ind Ltd カテプシンｌ阻害剤
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
GB9723407D0 (en) 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
HUP0004400A3 (en) 1997-11-05 2002-10-28 Novartis Ag Dipeptide nitriles, process for their preparation, pharmaceutical compositions comprising thereof and their use
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
JP2002539190A (ja) * 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物および組成物
HRP20010738B1 (en) 1999-03-15 2005-02-28 Axys Pharmaceuticals N-cyanomethyl amides as protease inhibitors
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
ATE244235T1 (de) 1999-09-13 2003-07-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
JP2003509410A (ja) 1999-09-16 2003-03-11 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシンインヒビターとしての化合物および薬学的組成物
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
US6576062B2 (en) 2000-01-06 2003-06-10 Tokyo Electron Limited Film forming apparatus and film forming method
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DK1362052T3 (da) * 2001-01-17 2007-07-09 Amura Therapeutics Ltd Inhibitorer af cruzipain og andre cysteinproteaser
EP1372655B1 (en) 2001-03-02 2008-10-01 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
SE521652C2 (sv) 2001-03-15 2003-11-25 Canag Diagnostics Ab En skivepitelcellcancerrelaterad fusionsgen och motsvarande fusionsprotein
US6492662B2 (en) 2001-04-16 2002-12-10 Ibm Corporation T-RAM structure having dual vertical devices and method for fabricating the same
KR20040015725A (ko) 2001-06-01 2004-02-19 액시스 파마슈티컬스 인코포레이티드 카텝신 ｓ 억제제로서의 화합물 및 약제학적 조성물
KR20040033048A (ko) 2001-09-14 2004-04-17 미츠비시 웰파마 가부시키가이샤 티아졸리딘 유도체 및 이의 약학적 용도
CA2460125A1 (en) * 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
AU2002340031A1 (en) 2001-10-02 2003-04-14 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
EP1446115B1 (en) * 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
WO2003075836A2 (en) * 2002-03-05 2003-09-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2003097617A1 (en) 2002-05-14 2003-11-27 Axys Pharmaceuticals, Inc. Cysteine protease inhibitors
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
JP2006504719A (ja) 2002-10-08 2006-02-09 メルク フロスト カナダ アンド カンパニー 骨粗しょう症の治療において有用なカテプシンｋ阻害剤としての４−アミノ−アゼパン−３−オン化合物
US7326719B2 (en) 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
CA2526694A1 (en) 2003-06-04 2004-12-16 John W. Patterson Amidino compounds as cysteine protease inhibitors
AU2004268707A1 (en) 2003-08-27 2005-03-10 Merck Frosst Canada Ltd Cathepsin inhibitors
US20070276019A1 (en) 2003-09-18 2007-11-29 Axys Pharmaceuticals, Inc. Haloalkyl Containing Compounds as Cysteine Protease Inhibitors
BRPI0410979A (pt) 2003-09-18 2006-07-04 Axys Pharm Inc composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
WO2005040142A1 (en) 2003-10-24 2005-05-06 Aventis Pharmaceuticals Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
EP1694357A1 (en) 2003-12-11 2006-08-30 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
JP2007516295A (ja) 2003-12-23 2007-06-21 アクシス・ファーマシューティカルズ・インコーポレイテッド システインプロテアーゼインヒビターとしてのアミジノ化合物
RU2006131043A (ru) 2004-01-30 2008-03-10 Шеринг Акциенгезельшафт (De) Соединения силинана в качестве ингибиторов цистеиновой протеазы
US7737300B2 (en) 2004-09-17 2010-06-15 Virobay, Inc. Processes and intermediates preparing cysteine protease inhibitors
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
EP1819667B1 (en) * 2004-12-02 2012-10-17 ViroBay, Inc. Sulfonamide compounds as cysteine protease inhibitors
EP1865940B1 (en) * 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
US20070038176A1 (en) 2005-07-05 2007-02-15 Jan Weber Medical devices with machined layers for controlled communications with underlying regions

Also Published As

Publication number Publication date
MX2007011617A (es) 2008-03-13
EA200702030A1 (ru) 2008-02-28
IL186102A (en) 2012-09-24
IL186102A0 (en) 2008-01-20
NZ561681A (en) 2011-01-28
AU2006227254B2 (en) 2011-09-01
RS52762B (sr) 2013-08-30
CA2602175C (en) 2012-11-27
US20070021353A1 (en) 2007-01-25
PT1865940E (pt) 2013-04-08
TWI384982B (zh) 2013-02-11
HK1111981A1 (en) 2008-08-22
NO340619B1 (no) 2017-05-15
BRPI0609695A2 (pt) 2011-10-18
CY1114075T1 (el) 2016-07-27
JP2008538212A (ja) 2008-10-16
EP2511257B1 (en) 2015-06-17
ES2400582T3 (es) 2013-04-10
EA201201550A1 (ru) 2013-08-30
WO2006102243A3 (en) 2007-04-19
KR101447897B1 (ko) 2014-10-07
EA017874B1 (ru) 2013-03-29
JP5209466B2 (ja) 2013-06-12
EP1865940A2 (en) 2007-12-19
IL221395A (en) 2014-05-28
EP1865940A4 (en) 2010-03-17
WO2006102243A2 (en) 2006-09-28
EP2511257A2 (en) 2012-10-17
JP2012254985A (ja) 2012-12-27
NO20170371A1 (no) 2007-12-19
US8450373B2 (en) 2013-05-28
AU2006227254A1 (en) 2006-09-28
EP2511257A3 (en) 2013-01-09
CA2602175A1 (en) 2006-09-28
DK1865940T3 (da) 2013-03-04
TW200700057A (en) 2007-01-01
HRP20130419T1 (en) 2013-06-30
LV13669B (en) 2008-06-20
US7488848B2 (en) 2009-02-10
EP1865940B1 (en) 2013-02-13
US8013183B2 (en) 2011-09-06
NO20075370L (no) 2007-12-19
US20100305331A1 (en) 2010-12-02
US20120190714A1 (en) 2012-07-26
KR20080007331A (ko) 2008-01-18
IL221395A0 (en) 2012-09-24
US20090170909A1 (en) 2009-07-02
US7696250B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
IL188618A0 (en) Hcv ns3 protease inhibitors
IL183308A0 (en) Cathepsin cysteine protease inhibitors
IL198401A0 (en) Hcv ns3 protease inhibitors
ZA200710386B (en) Aspartyl protease inhibitors
IL187814A0 (en) Aspartyl protease inhibitors
ZA200710337B (en) Aspartyl protease inhibitors
IL187510A0 (en) Proteases for pharmaceutical use
IL183850A0 (en) Hiv protease inhibitors
ZA200800072B (en) HCV NS3 Protease inhibitors
PL1865940T3 (pl) Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych
IL177055A0 (en) Silinae compounds as cysteine protease inhibitors
GB0513841D0 (en) Cysteine protease inhibitors
IL197965A0 (en) Di-fluoro containing compounds as cysteine protease inhibitors
ZA200710642B (en) Proteases for pharmaceutical use
EP1855672A4 (en) HIV PROTEASE INHIBITORS
EP1866277A4 (en) COMPOUNDS CONTAINING SULFONYL AS CYSTEINE PROTEASE INHIBITORS
ZA200804025B (en) Aspartic protease inhibitors
ZA200908771B (en) Cysteine protease inhibitors
ZA200902475B (en) HCV NS3 Protease Inhibitors
ZA200706305B (en) HIV protease inhibitors
GB0513839D0 (en) Cysteine protease inhibitors
GB0513840D0 (en) Cysteine protease inhibitors
ZA200708602B (en) Alpha ketoamide compounds as cysteine protease inhibitors
GB0513837D0 (en) Cysteine protease inhibitors
GB0513842D0 (en) Cysteine protease inhibitors